264 related articles for article (PubMed ID: 32178508)
1. Graft-versus-cancereffect and innovative approaches in thetreatment of refractory solid tumors.
Şahin U; Demirer T
Turk J Med Sci; 2020 Nov; 50(SI-2):1697-1706. PubMed ID: 32178508
[TBL] [Abstract][Full Text] [Related]
2. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
[TBL] [Abstract][Full Text] [Related]
3. Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer.
Karadurmus N; Sahin U; Basgoz BB; Arpaci F; Demirer T
World J Transplant; 2016 Dec; 6(4):675-681. PubMed ID: 28058217
[TBL] [Abstract][Full Text] [Related]
4. Graft-Versus-Solid-Tumor Effect: From Hematopoietic Stem Cell Transplantation to Adoptive Cell Therapies.
Barisic S; Childs RW
Stem Cells; 2022 Jun; 40(6):556-563. PubMed ID: 35325242
[TBL] [Abstract][Full Text] [Related]
5. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
Sinkovics JG
Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
7. Solid Tumor-Induced Immune Regulation Alters the GvHD/GvT Paradigm after Allogenic Bone Marrow Transplantation.
Dang N; Lin Y; Rutgeerts O; Sagaert X; Billiau AD; Waer M; Sprangers B
Cancer Res; 2019 May; 79(10):2709-2721. PubMed ID: 30936086
[TBL] [Abstract][Full Text] [Related]
8. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
9. Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.
Espinoza-Delgado I; Childs RW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):865-75. PubMed ID: 15485320
[TBL] [Abstract][Full Text] [Related]
10. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
11. Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors.
Childs R; Srinivasan R
Cancer J; 2002; 8(1):2-11. PubMed ID: 11895199
[TBL] [Abstract][Full Text] [Related]
12. Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.
D'Aveni M; Notarantonio AB; Bertrand A; Boulangé L; Pochon C; Rubio MT
Front Immunol; 2020; 11():989. PubMed ID: 32528476
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer.
Bishop MR; Fowler DH; Marchigiani D; Castro K; Kasten-Sportes C; Steinberg SM; Gea-Banacloche JC; Dean R; Chow CK; Carter C; Read EJ; Leitman S; Gress R
J Clin Oncol; 2004 Oct; 22(19):3886-92. PubMed ID: 15314059
[TBL] [Abstract][Full Text] [Related]
14. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
Shimoni A; Nagler A
Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions.
Lundqvist A; Childs R
J Immunother; 2005; 28(4):281-8. PubMed ID: 16000944
[TBL] [Abstract][Full Text] [Related]
16. Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.
Maloney DG
Leuk Lymphoma; 2003; 44 Suppl 3():S99-105. PubMed ID: 15202532
[TBL] [Abstract][Full Text] [Related]
17. Role of Regulatory T Cells in Tumor-Bearing Mice Treated with Allo-Hematopoietic Stem Cell Transplantation Plus Thymus Transplantation.
Hosaka N
J Immunol Res; 2018; 2018():7271097. PubMed ID: 30057919
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man.
Slavin S; Or R; Prighozina T; Gurevitch O; Aker M; Panighari S; Shapira M; Nagler A
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S54-7. PubMed ID: 10933190
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hemopoietic stem cell transplantation in solid tumors.
Carnevale-Schianca F; Ricchiardi A; Capaldi A; Bucci AR; Grignani G; Rota-Scalabrini D; Fizzotti M; Aliberti S; Aglietta M
Transplant Proc; 2005; 37(6):2664-6. PubMed ID: 16182778
[TBL] [Abstract][Full Text] [Related]
20. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
Tsirigotis P; Shimoni A; Nagler A
Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
